Sleep deprivation and organic effects in the central nervous system Dynamics of biomarkers in cerebrospinal fluid by Olsson, Martin
Sleep deprivation and organic effects 
in the central nervous system
Dynamics of biomarkers in cerebrospinal fluid
Master thesis in Medicine
Martin Olsson
Supervisor
Henrik Zetterberg
Institute of Neuroscience and Physiology
Programme in Medicine
Gothenburg, Sweden 2015
1
Table of Contents
Abstract.................................................................................................................................................3
Background...........................................................................................................................................4
Sleep physiology..............................................................................................................................4
Why sleep?..................................................................................................................................4
Normal sleep...............................................................................................................................6
Sleep deprivation and disease.........................................................................................................7
Biomarkers.......................................................................................................................................8
Amyloid beta...............................................................................................................................8
Neurofilament light.....................................................................................................................8
S-100B.........................................................................................................................................9
Tau.............................................................................................................................................10
Aim......................................................................................................................................................11
Material and Methods........................................................................................................................12
Study population............................................................................................................................12
Sleep deprivation protocol............................................................................................................13
Sleep surveillance..........................................................................................................................13
Actigraphy.................................................................................................................................14
Polysomnography......................................................................................................................14
Blood and CSF sampling.................................................................................................................15
Blood and CSF analysis...................................................................................................................16
Data collection and statistical methods.........................................................................................16
Ethics...................................................................................................................................................17
Lumbar puncture...........................................................................................................................17
Sleep deprivation...........................................................................................................................17
Permissions....................................................................................................................................17
Results.................................................................................................................................................18
Discussion...........................................................................................................................................21
Why do tau and  Aβ increase?.......................................................................................................21
Methodological weaknesses..........................................................................................................22
Conclusions.........................................................................................................................................24
Populärvetenskaplig sammanfattning................................................................................................25
Sömnbrist och den mänskliga hjärnan – finns svar i ryggmärgsvätskan?......................................25
Acknowledgements............................................................................................................................27
References..........................................................................................................................................28
2
Abstract
Master Thesis , Programme in Medicine
Sleep deprivation and organic effects in the central nervous system 
- Dynamics of biomarkers in cerebrospinal fluid
Martin Olsson, 2015, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Göteborg, 
Sweden. 
Objectives  This study addresses potential CSF and blood biomarkers that may be affected by 
controlled sleep deprivation in healthy human subjects. We hypothesize that relevant biomarkers 
might be found among those conventionally related to some forms of neuronal degeneration and 
damage. 
Methods Study participants were subjected to one period of sleep deprivation (5 nights with < 4 hrs
of sleep) and one period of controlled normal sleep (5 nights with 8 hrs in bed). Sleep was 
monitored by polysomnography and actigraphy. CSF was collected by a routine lumbar puncture in 
the morning following each period. CSF was also collected 3 days after the sleep deprivation period
(recovery). CSF analysis included total-tau (TT), phospho-tau (PT), amyloid β42 (Aβ42) and orexin
(OX).  Four healthy volunteers with self-reported normal sleep and no daytime excess sleepiness 
were included in the current interim analysis. 
Results CSF concentrations of TT, PT and Aβ42 remained relatively unchanged from the normal 
sleep to the sleep-deprived state. In contrast, there was a pronounced increase in the concentration 
of TT (270 and 605 ng/L), PT (40 and 82 ng/L) and Aβ42 (1001 and 1628 ng/L) following three 
days of recovery. OX, on the other hand, followed an expected pattern (from 754 to 857 and 638 
3
pg/mL, respectively) which corroborates that the observed changes in TT, PT and Aβ42 were 
unrelated to possible changes in CSF dynamics/volumes. 
Conclusions Recovery sleep following brief sleep deprivation induced pronounced changes in CSF 
concentrations of TT, PT and Aβ42. These markers have been associated with Alzheimer’s disease 
but their role in normal physiology is largely unknown. The observed changes may shed further 
light on sleep-associated physiological effects in the brain, particularly during recovery from sleep 
loss.
Key words Alzheimer's disease, amyloid β, cerebrospinal fluid, sleep, sleep-deprivation, tau.
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Background
Today we have the ability to analyse a wide range of biomarkers in cerebrospinal fluid.
Some of these are specific for nerve cell damage and glial cell damage  (1). There is also a great
amount  of  research  indicating  that  sleep  is  associated  with  a  number  of  health  issues  such  as
depression, cancer and obesity (2-5). Of certain interest is that an increased removal of Alzheimer-
associated amyloid β (Aβ) has recently been shown in live mice during sleep (6). An overview of
available literature shows a lack of knowledge on the specific effects of sleep deprivation on the
human neuron. 
Sleep physiology
Why sleep?
Sleep is an essential function in all animals. No species of animals have been found that,
with certainty, do not sleep (7). Even species who are dependent on maintaining consciousness at all
times, such as dolphins, have found ways around this by letting one cerebral hemisphere sleep at a
time (8).  Rats that are kept awake for prolonged periods shows another aspect of how vital sleep is
as they will eventually die in a septic like state  (9). It is hard to overestimate the importance of
sleep, but it is still largely unclear why we sleep. Fortunately recent studies have shed some new
light on this question.
The human central nervous system lacks lymphatic drainage in the way other tissues does.
Instead it is dependent on the glymphatic system for this function. In 2013 L. Nedergaard et al (6)
showed, in mice, that the exchange between the neuronal interstitial space and cerebrospinal fluid
was  increased  during  sleep  by enhanced  glymphatic  activity.  In  their  experiment  they  saw an
increase in volume of the interstitial space by 60% during sleep. Elevated clearance of amyloid β (A
β) was also  observed. Sleep was induced by anaesthesia which suggests that it is not a circadian
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effect but directly associated with sleep. 
There is evidence that sleep has both short- and long-term effects on the immune system.
Tufik et al has shown that sleep deprived rats  will have a 20% decreased volume of white blood
cells  after  one night of total  sleep deprivation  (10).  The effect were seen in all  used variables,
including lymphocytes,  monocytes,  neutrophils  and spleen  size.  Mice  will  also  have  a  smaller
chance  of  surviving  sepsis  if  not  allowed  to  sleep  (11).  Further  evidence  of  just  how closely
connected sleep is to the immune system and inflammation, is the fact that the well known immune
modulating cytokine TNF (tumor necrosis factor) is in itself a sleep inducer  (12).
A recent study on human test  subjects  found that one week of sleep deprivation caused
down-regulation of 444 genes and up-regulation of another 267 genes measured by detecting RNA
in whole blood  (13). The sleep-deprivation protocol used resulted in 5.7 hours of sleep per night
during the deprived period versus 8.5 hours during the sleep extended period. Many of the affected
genes are related to human immune function (14). This is a profound effect on human transciptome
even within what could be considered normal, or at least close to normal, sleeping patterns.
There are many more, established or possible, reasons for the evolution of sleep; too many
to be described in detail here, though some need a very brief mentioning: 
• Sleep is connected to endocrine processes such as growth hormone, cortisol and thyroid
-stimulating hormone secretion (15, 16).
• Human metabolism is affected by sleep. The effects is intricate and not fully understood, but
lack of sleep decrease insulin sensitivity and affects lipid metabolism (14, 16, 17)  .
• Sleep is important for memory processing and consolidation (18). 
• It has been theorized that REM sleep in particular is important for ontogenesis (19). 
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Normal sleep
In humans there are three main variables that constitutes normal sleep: Sleep duration, sleep
structure and timing in respect to circadian rhythm (20). Quantifying normal sleep is a hard, not to
say impossible task, since there are so many different variables and there is such great individual
variability in all of them  (20). Apart from genetic and environmental impact on these variables,
ageing will also affect them, with a relative increase in REM (rapid eye movement) sleep, decreased
length of sleep and changed circadian rhythm (20, 21) . 
As always one will also have to consider what endpoint is of the most importance when we
try to find out what is optimal or normal sleep. Different endpoints such as mortality, morbidity and
cognitive performance produce different results. For example; studies have shown that relatively
short sleep, six to seven hours, is associated with the lowest mortality  (22, 23) but recent sleep
recommendations still states that seven to eight hours of sleep is optimal for adults (24).
Sleep structure describes the stages of sleep and their length. There are four stages of sleep
(20, 25). They are designated N1, N2, N3 and REM, where N denotes nonREM. During normal
circumstances the brain will go through these in the aforementioned order. The first cycle of the
night will take approximately 90 minutes and every cycle thereafter will be progressively shorter.
Different stages seem to serve different purposes. The amount of deep sleep (N3 or slow wave
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Illustration 1 Hypnogram showing a normal sleep structure.
S1-S3 denotes nonREM stages 1-3.
sleep) will affect your feeling of sleepiness the most but REM sleep on the other hand is more
important for memory processing.
In sleep science terminology, timing is the time of sleep induction in relation to the subject's
circadian rhythm. Bad timing will affect your sleep structure and make your sleep less effective
with decreased amount of slow wave sleep  (26). Negative health effects of night shift work are
evidence  of  the  importance  of  timing.  Night  shift  workers  who  maintain  a  constant  day/night
rhythm and get a sufficient amount of sleep will still have a higher risk for disease (26).
One way to look at sleep requirement is the point when there is no daytime sleepiness. But
this is not without problems either, since there are sleep disorders, such as obstructive sleep apnea
(OSA), where some patients report no daytime sleepiness even though they may have a manifest
disease which impacts their health. As with most biological measurements we are left with a large
variety of what is normal. Sleepiness or the lack thereof is still the clinically most relevant marker
for healthy sleep habits. 
Sleep deprivation and disease
There are health conditions that have been linked to sleep, or lack thereof, in almost every
field of medicine. Examples are autoimmune disorders (27), cancer (3), cardiovascular disease (17)
and psychiatric conditions (2, 5) . Considering the effect of sleep on genetic expression, metabolism
and  our  immune  system,  this  should  come  as  no  surprise.  The  exact  pathways  and  if  sleep
disturbance is the cause or the symptom are not always clear. One example of this is Alzheimer's
disease; a progressive memory disorder characterized by neurodegeneration and accumulation of
Aβ and phosphorylated tau in the brain.  Some recent studies suggest that many common sleep
disorders may precede clinical disease (28). Also, lack of good sleep seems to be a risk factor for
AD  in  itself.  In  later  stages  of  AD,  sleep  disorders  are  very  common,  probably  because  of
degeneration of neurons involved in sleep regulation.
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Biomarkers
For the pilot part of this study we will examine four main biomarkers, and some variants of
these, in cerebrospinal fluid. Aβ and Tau were chosen because of the connection to AD. S-100B and
Neurofilament light, because of our initial hypothesis that sleep deprivation involves stress to the
central  nervous  system,  and  these  are  good  candidates  to  reflect  this.  Below  is  a  very  brief
introduction to these biomarkers together with an slightly more detailed explanation to why each of
these was chosen. Many more biomarkers, both in blood and CSF, will be analysed when we have
completed the protocol for all 16 participants. 
Amyloid beta
Amyloid beta (Aβ) is a class of 36 to 43 amino acids long peptides, the 42 amino acid form
of which is the main component of amyloid plaques found in Alzheimer patients’ brains (1, 29). Aβ
is created by enzymatic activity, where amyloid precursor protein (APP) is cut into beta peptides. If
these peptides get miss-folded they may acquire the ability to affect other beta peptides to miss fold
in the same manner, much like prion disease. Not only will these have similar form but they will
also gain the ability to adhere to each other and the build up of plaques can begin. The normal
function of beta amyloid is still under investigation.
What makes amyloid beta interesting from a sleep deprivation perspective is the connection
between sleep and Alzheimer's disease and the recent finding that amyloid beta clearance from the
central nervous system is increased during sleep (6). Of all the amyloid peptides, we have chosen
beta 42 because a previous study showed the most significant difference, in normal sleep versus
sleep deprived subjects, with this peptide (30). It is also believed to be the main culprit behind the
creation of plaques (29).
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Neurofilament light
 The three forms of neurofilament (light, medium and heavy) are a major part of the neuronal
cytoskeleton, especially in large myelinated axons (31) . They belong to the intermediate filament
family and provide structural support for the axon and decide its thickness. The diameter will decide
the conductive velocity of the fibre  (32).  Neurofilaments are expressed soley in neuronal cells.
Neurofilament light (NFL) is the most common and smallest of the three types of neurofilament and
is the only one able to form polymeres on it's own (33). Elevated concentration of NFL in CSF is
associated  with  various  neurodegenerative  diseases  such  as  amyotrophic  lateral  sclerosis,
Alzheimer’s disease (34) and Charcot-Marie-Tooth disease (35). NFL is already used clinically to
asses neuronal degeneration and therefore it is of interest to this study.
S-100B
S-100 is a family of calcium-binding proteins. They are present in a wide range of cells but
in the brain they are most prominent in astrocytes and oligodendrocytes. S100B is only expressed in
two subtypes  of astrocytes:  one that  surrounds blood vessels,  another  that  expresses NG-2 and
resides in the brain parenchyma and is believed to be a oligodendrocyte precursor  (36, 37). Its
functions are complex and include trophic effects at low concentrations, but toxic effects at higher
concentrations.  S100B  has  an  effect  on  the  neuronal  cytoskeleton  by  inhibiting  microtubule
assembly, a regulating role in the cell cycle and it plays a part in axonal proliferation, among other
things (36).
Clinically, S-100B can be used as a marker for neuronal damage. It has been shown that
elevated levels of the protein is present after head trauma  (38), in Alzheimer's disease  (39, 40),
Downs syndrome  (40) and other neurological and somatic diseases. Of certain interest is that a
recent  study  also  found  that  S-100B  levels  in  blood  increase  after  one  night  of  total  sleep
deprivation (41). 
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Tau
Tau is  an important protein involved in stabilizing the neuronal  microtubule  (42) of the
central nervous system. There are six isoforms of tau of which all are present in the brain.  They are
abundant in neurons but there are also low levels in other tissues and there is a small production in
astrocytes and oligodendrocytes  (43). Tau can affect tubular stability either by its isoform or by
phosphorylation, which makes the protein detach from the microtubules.
In Alzheimer's  disease it  is  hypothesized that Amyloid beta load will  eventually lead to
hyperphosphorylation and mis-folding of tau  (1). This can make the otherwise soluble protein to
form insoluble  aggregates  known as  tangles.  Tangles  are  a  central  part  of  Alzheimer's  disease.
Elevated levels of tau has also been detected after traumatic brain injury and is associated with poor
outcome (44). 
We have chosen to examine the CSF levels of tau and its phosphylated form in relation to
sleep  deprivation.  They  are  of  interest  to  sleep-deprivation  because  they  are  commonly  used
markers for neuronal injury and Alzheimer's disease progression (1), both of which we hypothesize
are associated with sleep.
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Aim
We aim to explore the possible effects of sleep deprivation on human brain physiology and
function  by  studying  cerebrospinal  fluid  and  blood  from  sleep-deprived  test  subjects.  We
hypothesize  that  there  is  a  connection  between  sleep  deprivation  and  elevated  levels  of  CSF
biomarkers related with neurodegeneration and neuronal damage. We also hypothesize that this may
contribute to the development of neurodegenerative disease such as Alzheimer’s.
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Material and Methods
Study population
This project was created as a pilot study for a larger project in which the author is still
involved. Data will be collected from the first four study participants as a proof of concept, but
research will carry on and include another 12 test subjects. In total, sixteen healthy test participants
between the age of 20 and 40 and with no sleep disturbances, will be included. Subjects with a
Body-Mass-index (BMI) above 30 kg/m2, continual use of medication or relevant chronic diseases
will be excluded. Our definition of normal sleep pattern includes self reported normal bedtime <
00.00, regular morning awakening hours 06.00-09.00, habitual sleep duration of between 6.5-8.5
hours  and  absence  of  sleep  disturbances
(such  as  chronic  insomnia/daytime
sleepiness/narcolepsy).  
The  Epworth  Sleepiness  Scale  (ESS)
was used to  further evaluate  excess daytime
sleepiness and a cut off score was set to <11.
Which is a standard value commonly used in
sleep deprivation protocols. Test subjects will
stop  using  caffeine  or  nicotine  at  least  two
days prior to the study period. Use of central
stimulating substances, by subjects, during the
experiment, will lead to exclusion. Of  the
four  subjects  in  our  pilot,  two  were  female
and two were nicotine users. 
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Figure 2: Flowchart of participant inclusion
Sleep deprivation protocol
The participants will be subjected to a period of partial sleep deprivation (5 consecutive
nights  consisting  of  a  maximum  of  four  hours  of  sleep  per  night)  with  two  baseline  nights,
consisting of eight hours total time in bed between 22.00-0800, prior to the sleep restriction period
in  accordance  to  a  standardized  protocol  (45).  The  participants  will  also  undergo  a  period  of
controlled normal sleep (five nights of eight hours total time spent in bed), thus making the test
subjects their own controls. The two periods will be separated by at least four weeks of normal
sleeping pattern without our influence to minimize the risk of interference. Half of the group of test
subjects will have the sleep deprivation period prior to the period of controlled normal sleep whilst
the other half will have the opposite arrangement. During the sleep-deprivation period participants
were not allowed to bring their own food to the lab. They were instead offered one standardized
meal (Frozen meal with <500 kcal) every night.
Sleep surveillance
During our study two different systems of sleep surveillance were used; polysomnography
(PSG) and actigraphy. Multiple methods ensures data quality and provides technical redundancy. 
PSG were used to retrieve data when subjects were in bed at the laboratory. The Actigraph were
used for the complete period to ensure that protocol is followed both at our laboratory and when at
home.  
During the sleep restriction period subjects arrived at the ward at 10 pm every night. They
were observed by staff  while  at  the  lab.  Bedtime  were  set  between 3  and 4  am and the  PSG
equipment were hooked up well in advance of bedtime. While in the controlled normal sleep period
participants slept at the laboratory during the first and last night. The first night were spent at the lab
to habituate and lessen the risk of the so called “first night effect”.
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Actigraphy
Actigraphy is a validated modality for testing total sleep time (46).  The actigraph is a small
device worn on the test subjects non dominant wrist, it will record data of ambient light and motion
which will later be evaluated in a validated software. It is comparable, but not quite as precise, as
the polysomnograph in the detection  of  sleep stages.  We have chosen to  use the “wGT3X-BT
Monitor”  for  sleep  surveillance  and  the  Actilife  software  for  data  analysis,  both  are  made  by
ActiGraph. Below is a an exampel of an automatic analysis with the Actilife software. 
Polysomnography
Polysomnography (PSG) is the gold standard for in depth evaluation of sleep in test subjects.
A PSG consists of a continuous recording of electrical activity in the brain (eeg), skeletal muscles
(emg), eye muscles (eog) and the heart (ecg). Other modalities can also be added, such as pulse
oxymetry and nasal air flow. Blinded data is later analysed by certified personel. Fig 3 shows how
data is visualized when using PSG. 
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Figure 3: Visualization of sleep data retrieved from an actigraph
The shadowed area represents sleep as interpreted by the Actilife software
Blood and CSF sampling
In the morning of the sixth day and another 3 days after the sleep restriction period, blood
and CSF will be obtained from the participants by veni- and lumbar puncture respectively. 
CSF will also be retrieved after the period of controlled normal sleep (five nights of eight hours
total time spent in bed), thus making the test subjects their own controls. 
CSF (10-12 ml) will be collected in polypropylene tubes, centrifuged (1300 x g, 10 min),
aliquoted and stored in 0.5 ml aliquots at -80oC pending analysis. Five ml blood will be collected in
an EDTA tube for plasma preparation and another 5 ml will be collected in a gel tube for serum
preparation. Following centrifugation (1300 x g, 10 min), plasma and serum will be aliquoted into
0.5 ml aliquots and stored at -80oC pending analysis.  
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Figure 4: A polysomnographic recording of a testsubject experiencing slow wave sleep
The top four rows represents different EEG projections. The following two rows shows eyemovements by EOG. Next is
an EMG of the tounge and last is a single ECG projection.
Blood and CSF analysis
CSF total tau (T-tau, a marker of cortical axonal integrity), phospho-tau (P-tau, a marker of
tau  phosphorylation  and  tangle  pathology),  neurofilament  light  (NFL,  a  marker  of  subcortical
axonal  integrity),  42  amino  acid  long  Aβ  fragments  (Aβ42,  marker  of  amyloid  metabolism),
soluble ,  as  well  as and S100B (markers of  astroglial  activation/injury)  will  be analysed using
commercial immunoassays. In addition to the CSF markers, serum samples will be analysed for T-
tau and NFL using immunoassays on an ultra-sensitive single molecule array (Simoa) platform.
Data collection and statistical methods
Since the data for this report will include only four test subjects, statistical analysis will be
futile. The data will be presented as is and variables will be looked upon separately and without
calculation of correlation, significance etc.
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Ethics
Lumbar puncture
The collection of cerebrospinal fluid by lumbar puncture is a well established method that involves
few risks. The main concerns regarding this method is pain during the procedure and head ache that
typically  begins  within  one  or  two  days  after  the  procedure,  and  last  another  day or  two.  To
minimize these risks we will strive to use the smallest possible diameter needles. The needles used
will  also  be  so  called  atraumatic  needles,  which  will  further  lessen  the  risk  of  post  puncture
headache (47, 48) . 
Sleep deprivation
The test subjects will be subjected to five days of restricted sleep. This will lead to discomfort in
itself  as  the  test  subjects  will  experience  sever  sleepiness.  There  is  also  an  increased  risk  of
accidents involved since sleep deprivation decreases attention and reaction time. The test subjects
will be informed of this risk and will be asked to avoid situations which demands full vigilance.
Examples of such situations are driving a vehicle and operating heavy machinery.
Permissions
The study has  been granted approval  from  the Regional  Ethical  Review Board in  Gothenburg,
Sweden. The Declaration of Helsinki and The Universal Declaration of Human Rights have been
considered and respected in the designing and execution of this study.
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Results
There were only small differences in CSF biomarker data between the normal sleep and
sleep-deprivation time periods (insignificant with so few data points). However, following recovery
sleep (three nights of unrestricted sleep after the sleep-deprivation period) considerable changes had
occurred. Total- and phopsho-tau levels increased more than 2-fold in 3 out of 4 subjects. The trend
was also seen in the the fourth subject but not quite as pronounced. Such levels are otherwise only
seen in AD patients. CSF levels of the 42 amino acid long senile plaque-associated form of Aβ also
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Table 1: CSF levels for each individual test subject and average biomarker levels in CSF including ratios between 
different time points.
* amyloid-β peptide Triplex Assay **INNOTEST® β-AMYLOID immunoassay  
NFL s-100B Aβ42* Aβ42**
1569 0,684 345 52 951 993 728
756 0,74 345 51 970 1018 957
668 0,979 1009 128 2084 1246 598
NFL s-100B Aβ42* Aβ42**
436 0,681 279 40 1040 995 614
153 0,685 296 43 1164 1089 778
162 0,71 669 85 1729 1232 602
NFL s-100B Aβ42* Aβ42**
119 0,519 123 20 657 816 688
157 0,537 150 23 734 932 734
158 0,53 172 27 782 971 547
NFL s-100B Aβ42* Aβ42**
158 0,609 300 46 1215 1124 985
245 0,652 287 44 1135 1034 959
198 0,654 570 87 1918 1268 804
NFL s-100B Aβ42* Aβ42**
570,5 0,623 261,8 39,5 965,686 982,0 753,8
327,8 0,654 269,5 40,3 1000,684 1018,3 857,0
296,5 0,718 605,0 81,8 1628,144 1179,3 637,8
0,57 1,05 1,03 1,02 1,04 1,04 1,14
0,90 1,10 2,24 2,03 1,63 1,16 0,74
Test subject A T Tau P Tau Orexin
Sleep extention
Sleep deprivation
Recovery
Test subject B T Tau P Tau Orexin
Sleep extention
Sleep deprivation
Recovery
Test subject C T Tau P Tau Orexin
Sleep extention
Sleep deprivation
Recovery
Test subject D T Tau P Tau Orexin
Sleep extention
Sleep deprivation
Recovery
Averages T Tau P Tau Orexin
Sleep extention
Sleep deprivation
Recovery
SD/SE ratio
Recovery/SD ratio
increased  significantly.  The  relative  increase  of  Aβ42  differed  in  an  unexpected  way between
methods. Opposite changes were seen in the CSF levels of orexin (decreased levels after recovery
sleep), corroborating that the tau and Aβ changes at this time point were not just reflecting changes
in CSF dynamics/volumes. The difference that can be seen in NFL were not consistent between test
subjects  and  both  increased  and  decreased  concentrations  were  observed.  There  is  also  some
interesting changes in s-100B, but to small to draw any conclusions at this point.
So far sleep data is limited to actigraphy and observation as the PSG recordings have not yet
been analysed by a certified PSG technician. What we do have is Actilife software visualization of
actigraph data. We have made both automatic and manual sleep time estimations. The exactness of
our rudimentary analysis's is not enough to use for data comparison but is enough to confirm that
protocol was mostly upheld. The only major departure from protocol was test subject D's last night
of controlled normal sleep, were the test subject had trouble falling  and staying asleep (While at the
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Table 2: CSF concentration of selected biomarkers
Normal sleep Sleep deprivation Recovery sleep
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sleep centre.  Further  discussion below).  Unfortunately this  is  probably the night  with the most
impact on CSF chemistry. This explains the deviation in orexin levels of subject D compared to the
other subjects. Some other departures from protocol were found but were minor and should not
effect  results.   During  the  recovery period  we  only  have  self  reported  data  of  sleep  duration.
Interestingly all subjects reported between 29 and 30 hours of sleep in the recovery period (between
9.7 hrs to 10 hrs per night on average) were most of the excess sleep were reported the first night
(12.5 h on average ranging from 10.5 to 13.5 h)
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Discussion
Why do tau and  Aβ increase?
The  above  results  are  indeed  unexpected.  Our  initial  expectation  were  to  see  a  rise  in
biomarkers  after  the  sleep-deprivation  period  followed  by  a  fall  in  CSF  concentrations  after
recovery.  There  are  many possible  explanations  for  the  dramatic  rise  in  amyloid  beta  and  tau
following recovery sleep, but first one needs to rise the question whether the high leves of Aβ and
Tau actually arise from the sleep deprivation itself and that there is a lag between the CNS insult
and the rise biomarkers.  
There is also some reason to believe that  Aβ and Tau might accumulate in neurons while
subjects are sleep deprived because glymphatic clearance  is hindered  (6). When the test subjects
later gets sleep in abundance, previously pooled peptides are excreted from the neurons and into the
interstitial space fluid (ISF). Aβ and Tau then continue from the ISF and into the cerebrospinal fluid.
This would support the previous findings by Nedergaard et al (6).
Another possible explanation would be an increase in synaptic activity, which is known  to
increase CSF levels of  Aβ. Holtzman et al estimates that 70% of ISF amyloid beta is transmited to
the ISF by synaptic endocytois (49, 50). They also suggest that this is done in an activity-dependent
manner. 
One finding that  might  support  the  idea  that  the  increased  Aβ levels  are  dependent  on
synaptic activity and regeneration is the big difference between methods. The two methods differ in
what antibodies are used. The INNOTEST® β-AMYLOID immunoassay detects complete strains
of Aβ in a precise way, but the not yet fully validated amyloid-β peptide Triplex Assay is also able
to detect  Aβ that has been truncated in a faulty way. One could speculate that the percentage of
faulty  Aβ will increase if the process of splitting amyloid precursor protein is forced to speed up.
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Moreover,  there  is  an  interesting  link  between  mammal  hibernation/torpor-states  and
elevated concentrations of highly phosphorylated tau in CSF (51). The exact mechanism is not well
understood and is specific to phospho tau but never the less is an interesting connection between our
findings and prolonged sleep like states in animals. It should be noted that hibernation/torpor state
does not  mean sleep  (52).  During torpor  state  mammals  experience sleep as a separate  part  of
torpor.
Methodological weaknesses
So far this study has far to few data points to draw definite conclusions even though the
results are convincing. As mentioned earlier, the results are not what we expected. Because of this
our design do not monitor the recovery period quite as rigorously as one would want. So far we
only have self reported data from this period. This is something that will be addressed in upcoming
experiment rounds. Among other things, we will ad actigraphic surveillance in the recovery period.
One could also question if there should have been a baseline period before the periods of sleep
under surveillance though the effect to CSF chemistry were probably minimal.
Because of logistical reasons PSG data has not yet been analysed. This does not have any
major impact on the findings so far as sleep data,  at  this time, is only used to make sure that
protocol was upheld. As mentioned earlier, under materials and methods, the actigraph is precise
enough to do this task. 
An  unfortunate  effect  of  polysomnography  and  sleep  labs  is  that  they  pose  a  risk  of
influencing the sleep of test subjects. The magnitude of this influence differs from small (usually) to
profound (seldom). A classic phenomenon where the monitoring might have a considerable impact
is the so called “First night effect”, meaning that the test subject get less quality and quantity of
sleep when he or she is not yet used to the setting. Test subject D experienced this phenomenon, as
her last night of controlled normal sleep was also her first night at the sleep centre. In response to
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this we decided to introduce a habituation night at the centre in the beginning of the controlled
normal sleep period. This will decrease the risk of first night effect in the upcoming rounds of our
experiment.
Among the first four test subjects, three experienced post dural puncture headache (PDPH).
This is more than expected but at this time we cannot say much. So far there seem to be a tendency
to have more PDPH when sleep deprived. There is evidence that sleep or time of day might effect
the amount of PDPH (53). Young age also seems to be a risk factor apart from those factors that can
be mitigated (as mentioned under Ethics). A point of caution is the fact that the one subject who did
not experience headache is also the subject with less pronounced increase in CSF biomarker levels.
This is something that needs to be considered when doing the final analysis of all test subjects.
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Conclusions
Recovery sleep following a prolonged period of sleep deprivation induces elevated levels in
CSF T-tau, P-tau and Aβ42. These markers are traditionally associated with brain neuropathological
changes in AD, but their role in normal physiology is currently largely unknown. Cell and animal
data suggest that tau and Aβ are secreted from neurons in an activity-dependent manner. There are
also data indicating that they may reflect synaptic and neuroaxonal plasticity. Finally, both tau and
Aβ expression are up regulated in mammals during hibernation. Perhaps this, along with sleep-
associated changes in CSF dynamics, may explain the results seen so far. 
These findings have grown our knowledge of known biomarkers and their correlation with
sleep deprivation. We have also gained increased understanding in the short and long term effects of
sleep  deprivation  on  neurocognitive  function  and  its  contribution  to  the  development  of
neurodegenerative diseases such as Alzheimer’s disease.  Our results also prompts many new areas
of further research.
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Populärvetenskaplig sammanfattning
Sömnbrist och den mänskliga hjärnan - finns svar i ryggmärgsvätskan?
Sömn är ett förvånansvärt lite utforskat område. Människan har länge vetat att god sömn är 
nödvändigt för god hälsa, samtidigt har vi fram till nyligen haft mycket vaga föreställningar om 
varför det är så. Ny forskning har dock börjat skrapa på ytan till de grundläggande fysiologiska 
mekanismerna som gör att vi måste sova. 2013 visade en forskargrupp för första gången hur 
skadliga ämnen förs ut ur hjärnans celler under sömn. Detta hade innan varit en teori som nu kunde 
bevisas genom ett sinnrikt  experiment på möss. Det ämne man såg föras ut ur hjärnan kopplar vi 
idag samman med demenssjukdomen Alzheimer. 
I vår pågående studie tittar vi på vad som händer med den vätska som omgärdar hjärnan och 
ryggmärgen och som kallas ryggmärgsvätska. Det är i den vätska de ämnen som förs ut ur 
hjärncellerna under sömn hamnar. Vi låter friska människor med normala sömnvanor utstå perioder 
med normal sömn och begränsad sömn. Efter varje period, som varar i fem dagar, tar vi prov på 
ovan nämnda vätska genom ett stick i ländryggen. Vi tar även prov tre dagar efter perioden med 
begränsad sömn. De ämnen som vi mäter har på olika vis kopplats samman med stress och skada på
olika typer av celler i hjärnan. 
Vad vi har sett så här långt är att halten av ämnen som fram för allt ökar vi Alzheimers 
sjukdom stigit dramatiskt tre dagar efter perioden med mindre sömn. Faktum är att värdena nått 
nivåer som annars bara ses vid just Alzheimers sjukdom. En möjlig förklaring kan vara att 
transporten av dessa ämnen ut ur hjärnans celler varit begränsad då deltagarna inte sovit så mycket 
som krävs. När de sedan får sova ”ikapp” så har dessa ämnen forsat ut ur cellerna och in i 
ryggmärgsvätskan. En annan möjlig eller bidragande förklaring är att omsättningen av nervcellernas
kopplingar till varandra, synapserna, ökar under sömn. Denna omsättning har visat medföra ökade 
halter av vissa av de ämnen som även stigit i vårt experiment. Det är även känt att många som 
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drabbas av Alzheimers sjukdom har sömnstörningar som förvärras under sjukdomens förlopp. 
Magnituden av våra resultat förvånar även oss. De ger stöd åt tidigare forskning samtidigt 
som de skapar nya frågeställningar.  Upptäckterna bidrar även med kunskap om mekanismer i 
människan som tidigare bara har studerats i djur.  Vi hoppas att detta kommer bidra med ökad 
förståelse om de grundläggande mekanismer som utgör sömn. Resultaten bidrar även till mer 
kunskap om Alzheimers sjukdom vilket är ett tillstånd som innebär ett stort lidande för drabbade 
och anhöriga samtidigt som kostnaderna för samhället är enorma och ökande.
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